Chaudhuri, KR, Odin, P. The challenge of non-motor symptoms in Parkinson’s disease. Prog Brain Res. 2010;184:325-341.
Barone, P, Antonini, A, Colosimo, C, et al. The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson’s disease. Mov Disord. 2009;24:1641-1649.
Kumar, S, Bhatia, M, Behari, M. Sleep disorders in Parkinson’s disease. Mov Disord. 2002;17:775-781.
Lees, AJ, Blackburn, N, Campbell, VL. The nighttime problems of Parkinson’s disease. Clin Neuropharmaco. 1988;11:512-519.
Tandberg, E, Larsen, JP, Karlsen, K. A community-based study of sleep disorders in patients with Parkinson’s disease. Mov Disord. 1998;13:895-899.
Verbaan, D, van Rooden, S, Visser, M, Marinus, J, van Hilten, JJ. Nighttime sleep problems and daytime sleepiness in Parkinson’s disease. Mov Disord. 2008;23:35-41.
Chaudhuri, R, Martinez-Martin, P, Rofle, KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2011;19:105-113.
Gallagher, DA, Lees, AJ, Schrag, A. What are the most important nonmotor symptoms in patients with Parkinson’s disease and are we missing them?
Mov Disord. 2010;25:2493-2500.
Rios Romenets, S, Creti, L, Fichten, C, et al. doxepin and cognitive behavioral therapy for insomnia in patients with Parkinson’s disease - a randomized study. Parkinsonism Relat Disord. 2013;19:670-675.
Nausieda, PA, Weiner, WJ, Kaplan, LR, Weber, S, Klawans, HL. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin Neuropharmacol. 1982;5:183-194.
Antczak, JM, Rakowicz, MJ, Banach, M, et al. Negative influence of L-dopa on subjectively assessed sleep but not on nocturnal polysomnographiy in Parkinson’s disease. Pharmacol Rep. 2013;65:614-623.
Askenasy, JJ, Yahr, MD. Reversal of sleep disturbance in Parkinson’s disease by antiparkinsonian therapy: a preliminary study. Neurology. 1985;35:527-532.
Adler, CH, Thorpy, MJ. Sleep issues in Parkinson’s disease. Neurology. 2005;64(12 Suppl 3):S12-S20.
Chahine, LM, Daley, J, Horn, S, et al. Association between dopaminergic medications and nocturnal sleep in early stage Parkinson’s disease. Parkinsonism Relat Disord. 2013;19:859-863.
Trenkwalder, C, Kies, B, Rudzinska, M, et al. Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011;26:90-99.
Canesi, M, Mariani, CB, Isaias, IU, Pezzoli, G. Night-time use of rotigotine in advanced Parkinson’s disease. Funct Neurol. 2010;25:201-204.
Giladi, N, Fichtner, A, Poewe, W, Boroojerdi, B. Rotigotine transdermal system for control of early morning motor impairment and sleep disturbances in patients with Parkinson’s disease. J Neural Transm. 2010;117:1395-1399.
Chaudhuri, KR, Martinez-Martin, P, Antonini, A, et al. Rotigotine and specific non-motor symptoms of Parkinson’s disease: a post hoc analysis of RECOVER. Parkinsonism Relat Disord. 2013;19:660-665.
Chaudhuri, RK, Martinez-Martin, P, Rolfe, KA, et al. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson’s disease. Eur J Neurol. 2012;19:105-113.
Romigi, A SP, Marciani, MG, Izzi, F, et al. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson’s disease: an open label 24-hour polysomnographic study. J Neural Transm. 2006;113:1909-1913.
Reichmann, H, Cooper, J, Rolfe, K, Martinez-Martin, P. Sleep duration and “on” time during different periods of the day and night in patients with advanced Parkinson’s disease receiving adjunctive ropinirole prolonged release. Parkinsons Dis. 2011;2011:1-8.
Zibetti, M, Rizzone, ZM, Angrisano, MA, et al. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson Disease. Acta Neurol Scand. 2013;127:e28-e32.
Amara, AW, Standaert, DG, Guthrie, S, et al. Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18:63-68.
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937-1943.
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241-248.
Rascol, O, Brooks, DJ, Melamed, E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365:947-954.
Olanow, CW, Hauser, RA, Jankovic, J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson’s disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord. 2008;23:2194-2201.
Müller, T, Klasser, M, Rieke, J, Ries, S, Schwartz, G, Ehret, R, and the Rasagiline Sleep Disturbances Study Group. Effect of rasagiline on sleep disturbances and fatigue in patients with Parkinson’s disease: a pilot study. Poster session presented at: 6th International Congress on Mental Dysfunctions & Other Non-Motor Features in Parkinson’s Disease; October 16-19, 2008; Dresden, Germany.
Müller, T, Hoffmann, JA, Dimpfel, W, Oehlwein, C. Improvements in sleep and mood after switch of Parkinson´s disease patients (PD) from selegiline to rasagiline. Eur J Neurol. 2011;18:244.
Chaudhuri, KR, Pal, S, DiMarco, A, et al. The Parkinson’s disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2002;73:629-635.
Johns, MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540-545.
Johns, MW. Reliability and factor analysis of the Epworth Sleepiness Scale. Sleep. 1992;15:376-381.
Forkmann, T, Scherer, A, Boecker, M, Pawelzik, M, Jostes, R, Gauggel, S. The Clinical Global Impression Scale and the influence of patient or staff perspective on outcome. BMC Psychiatry. 2011;11:83.
Atkinson, MJ, Sinha, A, Hass, SL, et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Qual Life Outcomes. 2004;2:12.
Abe, K, Hikita, T, Sakoda, S. Sleep disturbances in Japanese patients with Parkinson’s disease—comparing with patients in the UK. J Neurol Sci. 2005;234:73-78.
Chen, JJ, Swope, DM. Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease. J Clin Pharmacol. 2005;45:878-894.
Thebault, JJ, Guillaume, M. Phase I clinical trials of TVP-1012 (rasagiline mesylate), a selective inhibitor of monoamine oxidase B, for treatment of Parkinson’s disease. Move Disord. 1997;12(Suppl 1):106.
Stocchi, F, Rabey, JM. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. Eur J Neurol. 2011;18:1373-1378.